Aflac (AFL) In-Depth Stock Report
A supplemental health insurer with a large Japan franchise, priced on yen exposure, cancer and medical product persistency, and capital return.
Investment Summary
Every headline number this report produces, collected in one place before the analysis that derives them. All figures are computed live at page load, so this block reflects the market as of the moment you opened the page.
- Stable persistency and premium growth continue.
- Rising Japanese yields lift reinvestment returns.
- U.S. worksite business grows.
- Capital return remains generous.
- Aflac is a supplemental health and life insurer with a large Japan business.
- Stable margins and capital return are central.
- Yen and Japan are the main sensitivities.
- Adjusted earnings and persistency are the key numbers.
- Aflac sells supplemental health and life insurance, with about two-thirds of earnings from Japan and the rest from the U.S.
- Products include cancer, accident, hospital indemnity, and other coverage paid in addition to standard health insurance.
- The company holds a substantial fixed-income portfolio, much of it in yen, which makes currency and rates key drivers.
- The U.S. business sells through worksite marketing and has a diverse customer base.
- The equity debate is currency translation, Japan interest rates, and the pace of U.S. growth.
Executive Summary
Aflac has a durable brand and distribution in Japan, where it sells through partners such as Japan Post and agencies, giving it a recurring premium base.
Supplemental policies are simple, low-premium, and profitable, with strong persistency and predictable claims.
The yen exchange rate affects reported U.S.-dollar earnings and book value, and hedging attempts to reduce volatility.
Capital generation is strong, funding dividends and buybacks, with the dividend rising for many consecutive years.
The realistic thesis: a defensive, high-return insurer with steady capital return whose reported results can swing with currency and Japanese interest rates.
Industry & Market Backdrop
The broader competitive and macro environment AFL operates in — context a pure valuation table can't convey on its own.
Japan's aging population and demand for supplemental health coverage support long-term demand.
Rising Japanese yields could improve reinvestment returns over time.
U.S. worksite benefits demand grows as employers expand voluntary offerings.
Medical cost inflation and product regulation influence pricing and design.
Currency volatility affects reported earnings and capital ratios.
Live Key Statistics
Pulled live from BriMindInvest's market-data pipeline at page load — the same feed that powers /analysis/AFL. Fields the pipeline doesn't return this load are omitted rather than shown blank.
Business Overview
Aflac Japan selling cancer, medical, and life products through multiple channels.
Aflac U.S. selling supplemental products largely at the worksite.
A large investment portfolio supporting long-duration liabilities.
Group insurance and other smaller lines.
Segment Deep Dive
A closer look at each reporting segment individually, rather than treating the business as a single undifferentiated revenue line.
Japan is the primary earnings engine, with persistent policies and stable margins. Distribution partnerships are critical, and product refreshes address changing needs. Low interest rates have constrained investment returns.
U.S. products sold through employers and agents provide steady growth and diversification. Group and individual products serve a broad customer base, and digital enrollment is a growth lever.
Bond-heavy portfolios fund long-tail liabilities, and yield changes affect margins. Credit quality and currency-hedged structures are monitored.
Capital Allocation & Balance Sheet Philosophy
How management has historically chosen to deploy cash — buybacks, dividends, R&D, and acquisitions — and what that reveals about capital discipline.
The company returns most earnings via dividends and buybacks.
A long record of dividend increases is a core part of the investor case.
Regulatory capital in Japan and the U.S. is closely managed.
Hedging programs limit yen-dollar volatility in the investment portfolio.
Management & Governance
Leadership, incentive alignment, and governance structure — factors that shape execution risk independent of the underlying business model.
Leadership has emphasized capital efficiency, product innovation, and distribution partnerships.
Management provides clear guidance on capital deployment and earnings.
Governance is conventional; review the proxy for details.
Execution in Japan and U.S. growth are the main tests.
See exactly how we get AFL's fair-value range
| Method | Relevance | Implied Value |
|---|---|---|
| Our DCF Model | High | |
| Our P/E Based | Medium | |
| Our Book Value Based | Medium | |
| Graham Number | Medium | |
| PEG Ratio Based | Low | |
| ROIC Based | Medium | |
| FCF Yield Based | High |
Forecast Revenue and Free Cash Flow
5-Year Monte Carlo Simulation
Included with a subscription or a one-time purchase of this Aflac report:
- Fair value from 7 methods, weighted by relevance to this business
- 5-year financial forecast and DCF/earnings sensitivity grids
- Decomposed AI Score, Monte Carlo simulation, and institutional/analyst data
$3.99 is less than one bad options trade — see the model before you commit real money. And it goes straight to the small team building this, not a hedge fund's marketing budget.
Bull Case vs. Bear Case
- Stable persistency and premium growth continue.
- Rising Japanese yields lift reinvestment returns.
- U.S. worksite business grows.
- Capital return remains generous.
- Efficiency gains lift margins.
- A weaker yen reduces reported earnings.
- Japanese distribution partners reduce sales.
- Claims costs exceed expectations.
- Credit losses affect the investment portfolio.
- Regulatory changes limit products.
Related Reports
In-depth reports for other names in Aflac's comparable set.
4 catalysts and 4 risks we're tracking for AFL
| Catalyst | Expected Impact | Timeframe |
|---|---|---|
Included with a subscription or a one-time purchase of this Aflac report:
- Catalyst list, each tagged with expected impact and timing
- Risk register scored by probability and severity
- 4 key metrics to watch before the next earnings report
$3.99 is less than one bad options trade — see the model before you commit real money. And it goes straight to the small team building this, not a hedge fund's marketing budget.
What Would Change Our Mind?
Specific, falsifiable triggers — not vague sentiment — that would move us toward or away from the bull case above.
- Japanese rates rise while sales stay steady
- U.S. growth accelerates
- Capital return increases
- Yen weakness persists
- Key distribution partners cut sales
- Claims trends worsen
Competitive Positioning
Aflac's moat is brand recognition in supplemental insurance, distribution relationships, and underwriting data.
Competitors include Japanese life insurers and U.S. benefits providers such as Unum and MetLife.
Customer loyalty and persistency support stable earnings.
The vulnerability is concentration in Japan and regulatory or currency shifts.
Investor Decision Framework
A process for using this report, not a recommendation — how to weigh valuation, scenario spread, and your own risk tolerance.
- Own it if you want a defensive, high-capital-return insurer.
- Skip it if you want U.S. growth exposure or dislike currency risk.
- Track yen and persistency.
The BriMindInvest Edge
Why this report is different from asking a general-purpose AI chatbot about the stock.
- Every valuation number on this page is computed live from current market data through our own DCF, scoring, and Monte Carlo engines — not summarized or paraphrased from other analysts' reports the way a general chatbot would.
- The relevance-weighted fair value, reverse-DCF market-implied growth, fundamentals-based Monte Carlo, and scenario tables above are proprietary calculations you cannot get by asking a general-purpose AI for "AFL fair value" — those answers come from web summaries of other people's price targets, not a live, disclosed-assumption model.
- Our 1-year price-target model has a real, published backtest (see Model Track Record above where covered) — we show our work and our error rate rather than asserting accuracy.
- Numbers here are refreshed every time you load the page, not cached from a training cutoff months or years in the past.
Data Sources & Methodology
Valuation, price, and financial-statistics data in this report are fetched live from our production market-data pipeline (Yahoo Finance and Finnhub) at the time you loaded this page. The AI Score is a percentile ranking against our full covered stock universe, recomputed nightly. The fundamentals-based Monte Carlo and Bull/Base/Bear scenarios randomize growth rate, discount rate, and terminal growth around the same disclosed DCF assumptions used in the valuation table — they are not derived from resampled historical stock returns. The secondary historical-volatility simulation (2,000 bootstrap paths, seeded for reproducibility) uses the stock's own historical monthly returns and is shown separately because it measures a different thing (volatility) than the fundamentals-based model (intrinsic value).
This report is for informational and educational purposes only and does not constitute financial, investment, or tax advice, or a recommendation to buy or sell any security. All valuation models, price targets, and simulations are estimates based on historical and current data; actual results will differ, potentially substantially. Investing involves risk, including loss of principal. See our full Methodology and Disclaimer.
Free vs. Premium: What You're Getting
- Narrative overview and general bull/bear framing
- Headline price and basic company facts
- No live valuation model, AI Score, or forecast table
- Relevance-weighted fair value range and reverse-DCF market-implied growth
- 5-year financial forecast, DCF sensitivity grid, and Bull/Base/Bear scenario table
- Fundamentals-based Monte Carlo and decomposed AI Score with sub-factor components
- Real, published backtested accuracy where AFL is in our coverage set
Glossary of Key Terms
Plain-English definitions for the terms used throughout this report, for readers newer to equity valuation.
Frequently Asked Questions
Unlock Full AI-Powered Analysis
Get AI prediction signals, unlimited stock comparisons, portfolio analytics, and personalized watchlists — free for 14 days, no credit card required.
14-day free trial · No credit card required · Cancel anytime
Not ready to sign up? Get one free email a week instead.